Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

por Raffi, François, Rachlis, Anita, Brinson, Cynthia, Arasteh, Keikawus, Górgolas, Miguel, Brennan, Clare, Pappa, Keith, Almond, Steve, Granier, Catherine, Nichols, W. Garrett, Cuffe, Robert Liam, Jr, Joseph Eron, Walmsley, Sharon
Publicado 2015